Download PDF
Pharmacopsychiatry 2009; 42(2): 57-60
DOI: 10.1055/s-0028-1102911
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Relationship between Neuroleptic Extrapyramidal Syndromes and Patients’ All-Cause Mortality

J. Modestin 1 , M. Vogt Wehrli 1 , P. L. Stephan 1 , P. Agarwalla 1
  • 1University of Zurich, Department of Psychiatry (Burghölzli Hospital), Zurich, Switzerland
Further Information

Publication History

received 28.02.2008 revised 15.08.2008

accepted 03.09.2008

Publication Date:
23 March 2009 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: It is important to understand factors contributing to a neuroleptic-related increased mortality risk. The objective of this study was to test whether the occurrence of neuroleptic-induced extrapyramidal syndromes (EPS) including tardive dyskinesia (TD) is associated with an increased patients’ all-cause mortality.

Methods: In 1995, a sample of 200 patients on neuroleptics was assessed with regard to the presence of Parkinson syndrome, akathisia, and TD. By 2003–2004, i.e., during the following 8–9 year period, 63 patients had died. Patients who had died were compared with 120 patients known to be still alive with regard to several socio-demographic variables and the presence of EPS at the first examination.

Results: At the basic assessment, there were no significant differences between patients later still alive and deceased patients with regard to TD. The deceased patients were more frequently women, older, suffered more frequently from an organic disorder, had higher average scores for Parkinson syndrome and less frequently akathisia. Multivariate analysis confirmed age as the only factor contributing to the group difference. Repeating the meta-analysis by Ballesteros et al. (2000) after inclusion of our data, TD remains a weak but a significant predictor of death (OR=1.4).

Discussion: Neuroleptic-induced EPS of parkinsonism, akathisia, and TD did not contribute to the patients’ all-cause mortality in this study. The association between TD and mortality merits further attention.

References

  • 1 Ballesteros J, Gonzales-Pinto A, Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies.  J Clin Psychopharmacol. 2000;  20 188-194
    CrossrefPubMedGoogle Scholar
  • 2 Barnes TRE. A rating scale for drug-induced akathisia.  Br J Psychiatry. 1989;  154 672-676
    CrossrefPubMedGoogle Scholar
  • 3 Benkert O, Hippius H. Compendium of Psychiatric Pharmacotherapy, 5th ed. Heidelberg: Springer 2005
  • 4 Bennett DA, Beckett LA, Murray AM. et al . Prevalence of parkinsonian signs and associated mortality in a community population of older people.  N Engl J Med. 1996;  334 71-76
    CrossrefPubMedGoogle Scholar
  • 5 Byne W, Stamu C, Whjite L. et al . Prevalence and correlates of parkinsonism in an institutionalized population of geriatric patients with chronic schizophrenia.  Int J Ger Psychiatry. 2000;  15 7-13
    CrossrefPubMedGoogle Scholar
  • 6 Casey DE, Rabins P. Tardive dyskinesia as a life-threatening illness.  Am J Psychiatry. 1978;  135 486-488
    PubMedGoogle Scholar
  • 7 Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.  Am J Psychiatry. 2004;  161 414-425
    CrossrefPubMedGoogle Scholar
  • 8 Fahn S, Elton RL. and members of the UPDRS Development Committee .Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, eds. Recent Developments in Parkinson's Disease, vol.2 Florham Park NJ: Macmillan Health Care Information 1987: 153-164
    Google Scholar
  • 9 Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. Washington DC: United States Department of Health, Education and Welfare 1976: 534-537
  • 10 Halliday J, Farrington S, MacDonald S. et al . Nithsdale schizophrenia surveys 23: Movement disorders.  Br J Psychiatry. 2002;  181 422-427
    CrossrefPubMedGoogle Scholar
  • 11 Inada T, Koshiishi M, Ohnishi K. et al . The life expectancy of schizophrenic patients with tardive dyskinesia.  Hum Psychopharmacol Clin Exp. 1992;  7 249-254
    CrossrefPubMedGoogle Scholar
  • 12 Jones PB, Barnes TRE, Davies L. et al . Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia.  Arch Gen Psychiatry. 2006;  63 1079-1087
    CrossrefPubMedGoogle Scholar
  • 13 Joukamaa M, Heliovaara M, Knekt P. et al . Schizophrenia, neuroleptic medication and mortality.  Br J Psychiatry. 2006;  188 122-127
    CrossrefPubMedGoogle Scholar
  • 14 Kane JM, Leucht S, Carpenter D. et al . , eds The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders.  J Clin Psychiatry. 2003;  64 ((12, Suppl)) 21-22
    PubMedGoogle Scholar
  • 15 Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics.  Pharmacopsychiatry. 2006;  39 47-51
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Kucharski LT, Smith JW, Dunn DD. Mortality and tardive dyskinesia [letter].  Am J Psychiatry. 1979;  136 1228
    PubMedGoogle Scholar
  • 17 Leuner K, Müller WE. Dopamin in the prefrontal cortex and ist different modulation by conventional and atypical antipsychotics.  Pharmacopsychiatry. 2007;  40 ((Suppl.1)) S17-S26
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Lieberman JA, Stroup TS, MacEvoy JP. et al . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.  N Engl J Med. 2005;  353 1209-1223
    CrossrefPubMedGoogle Scholar
  • 19 Markkula J, Helenius H, Lauerma H. On the relationship of atypical and low-dose conventional antipsychotics with akathisia in a clinical patient population.  Nord J Psychiatry. 2007;  61 152-157
    CrossrefPubMedGoogle Scholar
  • 20 MacClelland HA, Dutta D, Metcalfe A. et al . Mortality and facial dyskinesia.  Br J Psychiatry. 1986;  148 310-316
    PubMedGoogle Scholar
  • 21 Mehta D, Mallya A, Volavka J. Mortality of patients with tardive dyskinesia.  Am J Psychiatry. 1978;  135 371-372
    PubMedGoogle Scholar
  • 22 Modestin J, Stephan PL, Erni T. et al . Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia.  Schizophr Res. 2000;  42 223-230
    CrossrefPubMedGoogle Scholar
  • 23 Modestin J, Vogt Wehrli M, Stephan PL. et al . Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.  Schizophr Res. 2008;  100 97-107
    CrossrefPubMedGoogle Scholar
  • 24 Montout C, Casadebalg F, Lagnaoui R. et al . Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients.  Schizophr Res. 2002;  57 147-156
    CrossrefPubMedGoogle Scholar
  • 25 Morens DM, Davis JW, Grandinetti A. et al . Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men.  Neurology. 1996;  46 1044-1050
    PubMedGoogle Scholar
  • 26 Sachdev P. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.  Austr N Z J Psychiatry. 2004;  38 445-449
    CrossrefPubMedGoogle Scholar
  • 27 Schneeweiss S, Setoguchi S, Brookhart A. et al . Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients.  Can Med Assoc J. 2007;  176 627-632
    CrossrefPubMedGoogle Scholar
  • 28 Schooler NR, Kane J. Research diagnoses for tardive dyskinesia.  Arch Gen Psychiatry. 1982;  39 486-487
    PubMedGoogle Scholar
  • 29 Shear MK, Frances A, Weiden P. Suicide associated with akathisia and depot fluphenazine treatment.  J Clin Psychopharmacol. 1983;  3 235-236
    CrossrefPubMedGoogle Scholar
  • 30 Tenback DE, Harten PN van, Slooff CJ. et al . Evidence that early extrapyramidal symptoms predict later tardive dyskinesa: a prospective analysis of 10 000 patients in the European Schizophrenia Outpatient Health Outomes (SOHO) Study.  Am J Psychiatry. 2006;  163 1438-1440
    CrossrefPubMedGoogle Scholar
  • 31 Harten PN Van, Matroos GE, Hoek HW. et al . The prevalence of tar-dive dystonia, tardive dyskinesa, parkinsonism and akathisia. The Curaçao Extrapyramidal Syndromes Study I.  Schizophr Res. 1996;  19 195-203
    CrossrefPubMedGoogle Scholar
  • 32 Wirshing WC. Movement disorders associated with neuroleptic treatment.  J Clin Psychiatry. 2001;  62 ((Suppl. 21)) 15-18
    PubMedGoogle Scholar
  • 33 Yagi G, Takamiya M, Kanba S. et al . Mortality rate of schizophrenic patients with tardive dyskinesia during 10 years: a controlled study.  Keio J Med. 1989;  38 70-72
    PubMedGoogle Scholar
  • 34 Yassa R, Mohelsky H, Dimitry R. et al . Mortality rate in tardive dyskinesia.  Am J Psychiatry. 1984;  141 1018-1019
    PubMedGoogle Scholar
  • 35 Yassa R, Jones BD. Complications of tardive dyskinesia: a review.  Psychosomatics. 1985;  26 305-313
    PubMedGoogle Scholar
  • 36 Youssef HA, Waddington JL. Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia.  Acta Psychiatr Scand. 1987;  75 74-77
    CrossrefPubMedGoogle Scholar

Correspondence

J. ModestinMD 

Department of Psychiatry (Burghölzli Hospital)

University of Zurich

Lenggstraße 31

8032 Zurich

Switzerland

Phone: +41/44/384 26 70

Fax: +41/44/384 27 19

Email: modestin@bli.uzh.ch

      >